In this review, we will discuss the clinical implications of the correlation between PD-1/PD-L1 and PI3K/AKT/mTOR pathway activation in the progression and treatment of NSCLC, and explore the current situation of relevant targeted drugs and immunotherapy for NSCLC. The gene discussed is CD274; the disease is non-small cell lung carcinoma.